Univariate and multivariate analyses of overall survival
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, years | 0.99 (0.97–1.01) | 0.297 | - | - |
| Gender (male vs. female) | 1.01 (0.75–1.38) | 0.925 | - | - |
| ECOG (1 vs. 0) | 1.85 (1.37–2.51) | < 0.001 | 1.93 (1.40–2.64) | < 0.001 |
| ECOG (2 vs. 0) | 0.59 (0.14–2.40) | 0.459 | 0.71 (0.17–2.92) | 0.636 |
| BMI, kg/m2 | 0.98 (0.93–1.03) | 0.433 | - | - |
| Smoking history (yes vs. no) | 0.96 (0.70–1.30) | 0.771 | - | - |
| Drinking history (yes vs. no) | 0.85 (0.59–1.22) | 0.380 | - | - |
| Diabetes history (yes vs. no) | 1.06 (0.77–1.46) | 0.718 | - | - |
| Surgery before chemotherapy (yes vs. no) | 0.90 (0.59–1.36) | 0.605 | - | - |
| Baseline stage (metastatic vs. locally advanced) | 1.70 (1.23–2.34) | 0.001 | 0.94 (0.57–1.53) | 0.789 |
| Baseline CA19-9 level, U/mL | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 |
| Liver metastases (yes vs. no) | 1.93 (1.43–2.62) | < 0.001 | 2.12 (1.34–3.34) | 0.001 |
| Multiple metastases (yes vs. no) | 1.57 (1.05–2.33) | 0.026 | 1.20 (0.78–1.84) | 0.419 |
| First-line regimen (GS vs. GnP) | 0.63 (0.45–0.89) | 0.008 | 0.69 (0.48–0.97) | 0.035 |
The bold values indicate P < 0.1 in the univariable analysis and P < 0.05 in the multivariable analysis.